This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hershman, D. Articles by Grann, V. R. Search for Related Content PubMed PubMed Citation Articles by Hershman, D. Articles by Grann, V. R. Social Bookmarking                            What's this?

Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis

From the Herbert Irving Comprehensive Cancer Center and Department of Medicine, College of Physicians and Surgeons, Joseph L. Mailman School of Public Health, Columbia University, New York, NY; and Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.

Address reprint requests to Victor R. Grann, MD, MPH, Health Outcomes Research, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, PH18-201A, 630 West 168th St, New York, NY 10032; email: vrg2{at}columbia.edu

PURPOSE: To estimate the effects on survival, quality-adjusted survival, and health care costs of using tamoxifen for primary prevention in subgroups of women at very high risk for breast cancer.

PATIENTS AND METHODS: A decision analysis was performed using a hypothetical cohort of women that included subgroups with atypical hyperplasia, Gail risk greater than 5, lobular carcinoma-in-situ, or two or more first-degree relatives with breast cancer. Data sources were the Breast Cancer Prevention Trial, the Surveillance, Epidemiology, and End-Results program, time trade-off preference ratings, the Group Health Cooperative of Puget Sound, and the United States Health Care Financing Administration.

RESULTS: Our model predicted that tamoxifen would prolong the average survival of cohort members initiating use at ages 35, 50, and 60 years by 70, 42, and 27 days, respectively. It would prolong survival even more for those in the higher-risk groups, especially those with atypical hyperplasia (202, 89, and 45 days). Tamoxifen use was also projected to extend quality-adjusted survival by 158, 80, and 50 days in the atypical hyperplasia group. For younger women in the highest risk groups, chemoprevention with tamoxifen was estimated to have cost savings or be cost-effective, both with and without quality adjustments.

CONCLUSION: Chemoprevention with tamoxifen may be particularly beneficial to women with atypical hyperplasia, 5-year Gail model risk greater than 5%, lobular carcinoma-in-situ, or two or more first-degree relatives with breast cancer. The benefits may be greater if tamoxifen is initiated before age 50 years rather than after and if the breast cancer risk reduction conferred by tamoxifen lasts longer than 5 years. For women with a very high risk of invasive breast cancer, chemoprevention with tamoxifen seems to be cost-effective.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Kerlikowske Evidence-Based Breast Cancer Prevention: The Importance of Individual Risk Ann Intern Med, November 17, 2009; 151(10): 750 - 752. [Full Text] [PDF]

				J. Cuzick, J. F. Forbes, I. Sestak, S. Cawthorn, H. Hamed, K. Holli, and A. Howell Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial J Natl Cancer Inst, February 21, 2007; 99(4): 272 - 282. [Abstract] [Full Text] [PDF]

				M. N. Levine, P. A. Ganz, and D. G. Haller Economic Evaluation in the Journal of Clinical Oncology: Past, Present, and Future J. Clin. Oncol., February 20, 2007; 25(6): 614 - 616. [Full Text] [PDF]

				R. S. Svatek, J. J. Lee, C. G. Roehrborn, S. M. Lippman, and Y. Lotan The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1485 - 1489. [Abstract] [Full Text] [PDF]

				K. Anderson, J. S. Jacobson, D. F. Heitjan, J. G. Zivin, D. Hershman, A. I. Neugut, and V. R. Grann Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med, March 21, 2006; 144(6): 397 - 406. [Abstract] [Full Text] [PDF]

				C J Fabian, B F Kimler, M S Mayo, and S A Khan Breast-tissue sampling for risk assessment and prevention Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213. [Abstract] [Full Text] [PDF]

				Y. Lotan, J. A. Cadeddu, J. J. Lee, C. G. Roehrborn, and S. M. Lippman Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes J. Clin. Oncol., March 20, 2005; 23(9): 1911 - 1920. [Abstract] [Full Text] [PDF]

				C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]

				B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]

				E. M. Ozanne and L. J. Esserman Evaluation of Breast Cancer Risk Assessment Techniques: A Cost-effectiveness Analysis Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2043 - 2052. [Abstract] [Full Text] [PDF]

				D. L. Thull and V. G. Vogel Recognition and Management of Hereditary Breast Cancer Syndromes Oncologist, February 1, 2004; 9(1): 13 - 24. [Abstract] [Full Text] [PDF]

				A. Decensi, C. Robertson, G. Viale, F. Pigatto, H. Johansson, E. R. Kisanga, P. Veronesi, R. Torrisi, M. Cazzaniga, S. Mora, et al. A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers J Natl Cancer Inst, June 4, 2003; 95(11): 779 - 790. [Abstract] [Full Text] [PDF]

				R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343. [Abstract] [Full Text] [PDF]

				V. R. Grann, J. S. Jacobson, D. Thomason, D. Hershman, D. F. Heitjan, and A. I. Neugut Effect of Prevention Strategies on Survival and Quality-Adjusted Survival of Women With BRCA1/2 Mutations: An Updated Decision Analysis J. Clin. Oncol., May 15, 2002; 20(10): 2520 - 2529. [Abstract] [Full Text] [PDF]

				S. M. Lippman and W. Ki Hong Cancer Prevention by Delay : Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002. Clin. Cancer Res., February 1, 2002; 8(2): 305 - 313. [Full Text] [PDF]

				V. C. Jordan and M. Morrow Chemoprevention of Breast Cancer: A Model for Change J. Clin. Oncol., January 1, 2002; 20(1): 1 - 3. [Full Text] [PDF]